The pharmaceutical industry is continuously evolving, with increasing demand for high-performance Active Pharmaceutical Ingredients (APIs). Dulaglutide, a GLP-1 receptor agonist, is a key copyrightple of this trend. To fulfill this demand, US-based manufacturing services are gaining traction. These or